CRL Operating cash flow
Operating cash flow at Charles River Laboratories rose to $738M in fiscal 2025, from $735M in 2024.
Net cash provided by operating activities, as filed.
SOURCE: us-gaap:NetCashProvidedByUsedInOperatingActivities · EDGAR CompanyFacts · CIK 1100682 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$738M
FY2024 $735M
HIGH$761M FY2021
LOW$620M FY2022
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Operating cash flow | Change |
|---|---|---|
| FY2025 | $738M | +$3M |
| FY2024 | $735M | +$51M |
| FY2023 | $684M | +$64M |
| FY2022 | $620M | $-141M |
| FY2021 | $761M | — |
More SAME DATA, OTHER VIEWS
Operating cash flow across coverage → · CRL company view →
Revenue · Net income · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.